• Company Type For Profit
  • Contact Email info@mitrassist.com
  • Phone Number 972.260.7000

MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.

MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve

to work in unison with it and to enhance valve functionality.

MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.

Lists Featuring This Company

Middle East Pharmaceutical Companies
767 Number of Organizations • $6.1B Total Funding Amount • 344 Number of Investors
Middle East Acquired Companies
1,644 Number of Organizations • $46.4B Total Funding Amount • 2,018 Number of Investors
Israel Biotechnology Companies
692 Number of Organizations • $9.1B Total Funding Amount • 1,128 Number of Investors
Middle East Health Diagnostics Companies
410 Number of Organizations • $2B Total Funding Amount • 343 Number of Investors
on Nov 1, 2017.

Frequently Asked Questions

Where is MitrAssist's headquarters? MitrAssist is located in Misgav Dov, HaMerkaz, Israel.Who invested in MitrAssist? MitrAssist has 11 investors including Haiheng capital and 6 Dimensions Capital.How much funding has MitrAssist raised to date? MitrAssist has raised .When was the last funding round for MitrAssist? MitrAssist closed its last funding round on Sep 26, 2023 from a Series C round.Who are MitrAssist's competitors? Alternatives and possible competitors to MitrAssist may include Pliant Therapeutics and Advaxis.